Free tool
ELN genetic risk stratification.
Enter the findings from diagnosis. See the ELN genetic risk group in AML, for intensive (2022) or less-intensive (2024) therapy, and exactly why.
Döhner et al., Blood 2022. Mainly based on results in intensively treated patients.
Döhner et al., Blood 2024. For newly diagnosed AML treated with HMA alone, HMA plus venetoclax, or azacitidine plus ivosidenib (IDH1-mutated AML).
Try an example profile
How it works
- Choose ELN 2022 (intensive therapy) or ELN 2024 (less-intensive therapy). Findings both use, such as NPM1, FLT3-ITD and TP53, stay ticked when you switch.
- Tick every finding reported at diagnosis. Anything left unticked is treated as not detected.
- The result is the guideline’s risk group, applying its precedence rules. Combinations the guideline does not resolve are flagged for clinical review instead of being forced into a group.
- “Decisive findings” shows which findings the result hinges on. Click one to see what happens without it.
- Your selections stay in your browser. A shared link keeps them after the
#in the address, which browsers do not send to servers.
Source and limits
- Implements Table 6 of Döhner et al., Blood 2022;140(12):1345–1377. The table is mainly based on results in intensively treated patients, and the guideline notes that initial risk assignment may change during treatment based on measurable residual disease (MRD) analyses.
- Implements Table 1 of Döhner et al., Blood 2024;144(21):2169–2173. It does not apply after prior HMA treatment, has limited relevance after prior myeloproliferative neoplasm or HMA exposure (including AML after antecedent MDS), and does not cover low-dose cytarabine plus venetoclax. The authors expect it to be refined.
- An independent implementation, not affiliated with or endorsed by the ELN.
- A reference tool for healthcare professionals. It does not diagnose, recommend treatment, or replace clinical judgment. Do not enter patient identifiers; none are needed.